Dec 16, 2021
For years, policymakers across the political spectrum have sought to make the U.S. healthcare system more transparent. Unfortunately, the status quo too often incentivizes policies and practices that seem designed to keep patients in the dark about the real cost of...
Dec 2, 2021
As we near the end of a tumultuous year in politics, the fate of the Build Back Better Act (BBBA), a massive social spending bill and a centerpiece of President Biden’s domestic policy agenda, is still up in the air. Among the vast sea of policies included in the BBBA...
Nov 23, 2021
On November 9, 2021, ICER released its draft evidence report, “Tirzepatide for Type 2 Diabetes.” This is the first step in ICER’s process that is expected to conclude with the release of a final report in February 2022. Diabetes is a chronic condition in which a...
Nov 3, 2021
During the October 20, 2021, Senate Finance Hearing, Health Insurance Coverage in America: Current and Future Role of Federal Programs, the areas where each party agrees to disagree are stark, but the places where change for patients is possible exists. It is our aim...
Oct 14, 2021
On August 24, 2021, ICER released a revised version of a final evidence report from 2018 evaluating the clinical and cost effectiveness of three emerging treatments for hereditary angioedema. Unfortunately, while ICER tried to update its analysis — supposedly to...
Sep 27, 2021
On August 18, 2021, ICER released its draft evidence report, “Tezepelumab for Severe Asthma: Effectiveness and Value.” This is the first step in ICER’s standard process that – after a period of public comment – will result in the release of final evidence report,...
